Cited by 1,389Dementia and Cognitive Impairment ResearchCancer-related cognitive impairment studiesCognitive Functions and Memory

The characterisation of subjective cognitive decline

Open access
Jessen, Frank, Amariglio, Rebecca E, Buckley, Rachel F, van der Flier, Wiesje M, Han, Ying, Molinuevo, José Luis, Rabin, Laura, Rentz, Dorene M +6 more·2020·The Lancet Neurology

Abstract

A growing awareness about brain health and Alzheimer's disease in the general population is leading to an increasing number of cognitively unimpaired individuals, who are concerned that they have reduced cognitive function, to approach the medical system for help. The term subjective cognitive decline (SCD) was conceived in 2014 to describe this condition. Epidemiological data provide evidence that the risk for mild cognitive impairment and dementia is increased in individuals with SCD. However, the majority of individuals with SCD will not show progressive cognitive decline. An individually tailored diagnostic process might be reasonable to identify or exclude underlying medical conditions in an individual with SCD who actively seeks medical help. An increasing number of studies are investigating the link between SCD and the very early stages of Alzheimer's disease and other neurodegenerative diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(19)30368-0

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SCD is regarded as the first clinical manifestation in the AD continuum.

    “Subjective cognitive decline (SCD), the first clinical manifestation in the AD continuum, is self-experienced decline in cognitive function without evidence of objective cognitive impairment [3–5].”

    From Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease (2020) · cites this paper as [5]

    In “SCD and the Alzheimer’s disease research framework” (page not supplied), the paper places subjective cognitive changes in stage 2, the late preclinical phase of the Alzheimer’s disease continuum. But “Conclusions and future directions” says SCD could be the first symptom of an incipient neurodegenerative disease and is not an indicator of future cognitive decline for most individuals. Calling SCD *the* first clinical manifestation of the AD continuum omits those qualifications. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Subjective cognitive decline may also be caused by other underlying health conditions.

    “SCD may also be caused by other underlying health conditions (see Prevalence of Subjective Cognitive Decline).254”

    From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [254]

  • Subjective cognitive decline often prompts medical attention, and a formal diagnosis can help distinguish experiences potentially related to higher dementia risk from experiences less likely to be related, such as other underlying health conditions.

    “Subjective cognitive decline often prompts medical attention, and a formal diagnosis can help distinguish experiences potentially related to higher dementia risk from experiences less likely to be related, such as other underlying health conditions.”

    From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [280]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jessen, F., Amariglio, R. E., Buckley, R. F., van der Flier, W. M., Han, Y., Molinuevo, J. L., Rabin, L., Rentz, D. M., Rodriguez-Gomez, O., Saykin, A. J., Sikkes, S. A. M., Smart, C. M., Wolfsgruber, S., & Wagner, M.
Affiliations
  • University of Cologne (DE)
  • Brigham and Women's Hospital (US)
  • Capital Medical University (CN)
  • The Graduate Center, CUNY (US)
  • Indiana University Indianapolis (US)
  • University of Victoria (CA)
  • German Center for Neurodegenerative Diseases (DE)
  • University Hospital Bonn (DE)
Corresponding author
Jessen, Frank
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2020-03
Volume
19
Issue
3
Pages
271-278
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2998968185
Cited by
1,389
References
66
Citations by year
2026: 209 · 2025: 265 · 2024: 270 · 2023: 233 · 2022: 197 · 2021: 151 · 2020: 61 · 2012: 1
FWCI
26.54
Type
journal article
Language
en
Open access
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • VU Research Portal (publishedVersion, other-oa)
  • PubMed Central (acceptedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion)
  • DZNE Pub (submittedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
  • Division of Materials Research
  • ZonMw
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • Biogen
  • Roche
  • Bundesministerium für Bildung und Forschung (01ED1508)
  • National Natural Science Foundation of China (1R01AG058825–01A1)
  • Schweizerische Akademie der Medizinischen Wissenschaften (61633018)
  • National Institute on Aging (R01 AG019771, U01 AG024904, P30 AG010133)
  • Horizon 2020 Framework Programme (115985, 115952, AMYPAD EU-EFPIA IMI 2, MOPEAD EU-EFPIA IMI 2)
  • Novartis Pharma
  • Eli Lilly and Company
  • General Electric
  • Meso Scale Diagnostics
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Cognitive Functions and Memory
Keywords
subjective cognitive decline, mild cognitive impairment, dementia risk, Alzheimer's disease, early Alzheimer's disease, neurodegenerative diseases, cognitive decline, diagnostic workup, brain health
MeSH terms
Alzheimer Disease, Brain, Cognition, Humans, Neuropsychological Tests, Disease Progression, Diagnostic Self Evaluation, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review